In the early stages of a development project you will want to clearly picture the market potential of a project. An Early Market Access Strategy is aimed at providing this type of insight.
Market access strategy is an important part of aligning your messaging with the evidence requirements of local reimbursement authorities/agencies and payers. This will help your medicinal product onto the most effective path toward successful market commercialisation.
Timely support with early market access strategy will enable you to develop solid value propositions. Those will underpin your efforts in gaining patient access in the most efficient way and without detours.
Our work includes identifying important strategic milestones, such as:
– A review of available materials to identify gaps. Those will determine relevant health economic outcomes research that will strengthen your evidence package.
– Assistance with developing a price strategy.
– Help in defining and fine-tuning your value message for relevant markets.
A market access strategy is to be created early to avoid access hold-ups, to be on par with local requirements and clearly define the investment potential.
HTA/reimbursement submission strategy
Market Landscape review
Susanne Schuurman
Staffan Thunell
Founding partner
BSc Economics and BA
Staffan has a long background in entrepreneurship within the life science industry. He has 20+ years experience from positions as Founder, Chairman, CEO and CFO within medical affairs consulting and small pharma. Previously Staffan worked in executive positions in big pharma and specialty pharma companies.
